A new interleukin-1 (IL-1)-beta blocking monoclonal antibody, Canakinumab (ACZ885), was recently found to be an effective option to encourage effectiveness besides being well tolerated in children with sJIA (systemic juvenile idiopathic arthritis).

This finding was disclosed in a phase II study presented at PReS 2009, a joint congress with the 2009 Congress of the European League against Rheumatism (EULAR) in Copenhagen, Denmark.

From Sciencedaily.com:

Systemic Juvenile Idiopathic Arthritis (sJIA) is one of the five major types of Juvenile Idiopathic Arthritis (JIA) (along with oligoarticular JIA, polyarticular JIA, enthesitis related arthritis and psoriatic arthritis). sJIA is characterised by arthritis, fever and a salmon-pink rash. Systemic JIA can be challenging to diagnose because the fever and rash come and go. It affects males and females equally, unlike the other two subtypes of JIA. It is the most difficult JIA subtype to be treated. Steroids are the only effective drugs but are associated with severe adverse events including growth failure and osteoporosis.

JIA is considered to be one of the most common chronic inflammatory diseases of childhood that affects approximately 1 in every 1,000 children. sJIA is the most severe subtype of JIA.

Tags: Canakinumab, sJIA, steroids, systemic juvenile idiopathic arthritis

Posted in buy steroids, Steroid Cycles, steroid nation, Steroids and Anabolic Steroids